학술카지노사이트 샘플(의학논문카지노사이트)

원문만성 신질환자에서 빈혈에 대한 페기네사타이드(peginesatide)의 효능은 2상 임상시험을 통해 입증되었다. 시약투여 전 12주 동안 투석과 조혈자극제 치료를 모두 안 받은 환자들이 초기 페기네사타이드 용량(체중대비용량, 절대용량)과 투여경로(정맥주사, 피하주사), 투여빈도(2주 1회, 4주 1회)에 따라 10군으로 순차적으로 배정되었다. 전체 환자 중에서는 96%의 환자에서 헤모글로빈 반응이 나타났다. 헤모글로빈의 증가에서는 용량반응관계가 보였다. 피하주사나 정맥주사를 유사한 용량으로 투여했을 경우 두 환자군에서 비슷한 수준의 헤모글로빈 반응이 나타났다. 헤모글로빈의 빠른 상승과 1 g/dL 이상의 헤모글로빈 변동은 4주 1회 투여하는 환자보다 2주 1회 투여하는 환자에서 더 많이 일어나는 경향이 있었다. 본 연구는 비투석 만성 신질환자에서 4주 1회 페기네사타이드를 투여하는 것이 헤모글로빈 수치를 증가시키거나 유지하는 데 효과적이라는 것을 처음으로 입증했다는 점에서 의미가 있다. 에포에틴 알파(epoetin alfa) 치료 받고 있는 투석 환자는 성공적으로4주 1회의 페기네사타이드 치료로 바꿀 수 있다는 것이 3상 임상시험을 통해 밝혀졌다.
Reference: Source:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3377433/

원문카지노사이트The efficacy of peginesatide in the treatment of anemia in 카지노사이트 with CKD is proven in a Phase 2 clinical trial. 카지노사이트 who had received neither dialysis nor an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten groups according to initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and frequency (once every-2-week vs. every-4-week dosing). In all 카지노사이트, 96% showed a hemoglobin (Hb) response, and Hb increase showed a dose-response relationship. When similar dose was given by intravenous or subcutaneous injection, both patient groups showed a similar level of Hb response. There was a tendency for the 카지노사이트 who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb over 1 g/dL than in 카지노사이트 who received once every-2-week dosing. The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 카지노사이트. It was shown in a Phase 3 clinical trial that dialysis 카지노사이트 being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

카지노사이트본 검토The efficacy of peginesatide in the treatment of anemia in 카지노사이트 withchronic kidney disease (CKDis) has beenproven in a Phase 2 clinical trial. 카지노사이트 who had received neither dialysis nor an erythropoiesis-stimulating agent in the 12 weeks prior to theadministrationof the test drug were sequentially assigned to one of ten groups according to initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (once every-2-week vs. every-4-week dosing).InAmongall 카지노사이트, 96% showed a hemoglobin (Hb) response, andHbtheincreasein Hbshowed a dose-response relationship. When similar dose wasgivenadministeredby intravenous or subcutaneous injection, both patient groups showed a similar level of Hb response. There was a tendency for the 카지노사이트 who received once every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb over 1 g/dL than in 카지노사이트 who received once every-2-week dosing. The significance of the present study is that it was the first study to prove that once every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 카지노사이트. It was shown in a Phase 3 clinical trial that dialysis 카지노사이트 being treated with epoetin alfa can successfully transition to once every-4-week dosing of peginesatide.

프리미엄교정Thisestudy aimed to test theefficacy of peginesatide inthetreatingment ofanemia in 카지노사이트 with chronic kidney disease (CKD)has been proven inby usinga Phase 2 clinical trial.Our study population consisted ofPpatients whohadwere notreceived neitherondialysisnoror receivedan erythropoiesis-stimulating agent in the 12 weeks prior totheadministeringration ofthe test drug. were The population was divided intosequentially assigned to one oftengroupscohortsaccording tothat differed in theinitial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (onceevery-2-week vs. every-4-week dosing); each patient was sequentially assigned to a cohort. Among all 카지노사이트, 96% showed a hemoglobin (Hb) response, andthe increase in Hb showedan evidentdose-response relationshipwas observed. The Hb responses were similarWwhensimilarthedoses wasadministered by intravenousor andsubcutaneous injections,were similarboth patient groups showed a similar level of Hb response. There was a tendency for tThe 카지노사이트 who receivedonceevery-4-week dosing tended to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in the 카지노사이트 who received once every-2-week dosing.To the best of our knowledge,The significance ofthe present study isthat it wasthe firststudyto prove thatonceevery-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels innon-dialysisCKD카지노사이트 not undergoing dialysis. It was shown in aAPhase 3 clinical trialshowedthat dialysis 카지노사이트 being treated with epoetin alfa can successfully transition toonceevery-4-week dosing of peginesatide.

최종검토This study aimed to test the efficacy of peginesatide in treating anemia in 카지노사이트 with chronic kidney disease (CKD) by using a Phase 2 clinical trial. Our study population consisted of 카지노사이트 who were not on dialysis or received an erythropoiesis-stimulating agent in the 12 weeks prior to administering the test drug. The population was divided into ten cohorts that differed in the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (every-2-week vs. every-4-week dosing); each patient was sequentially assigned to a cohort. Among all 카지노사이트, 96% showed a hemoglobin (Hb) response, and an evident dose-response relationship was observed. The Hb responses were similar when the doses administered by intravenous and subcutaneous injections were similar. The 카지노사이트 who received every-4-week dosing tended to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than the 카지노사이트 who received every-2-week dosing. To the best of our knowledge, the present study is the first to prove that every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in CKD 카지노사이트 not undergoing dialysis. A Phase 3 clinical trial showed that dialysis 카지노사이트 being treated with epoetin alfa can successfully transition to every-4-week dosing of peginesatide.

일반교정 A Phase 2 clinical trial showed thatThe efficacy ofpeginesatidewas efficaciousinthetreatingment ofanemia in 카지노사이트 with chronic kidney disease (CKD)has been proven in a Phase 2 clinical trial. 카지노사이트 whohadwere not received neitherondialysisnoror receivedan erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of tengroupscohortsaccording totheinitial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (onceevery-2-week vs. every-4-week dosing). Among all 카지노사이트, 96% showed a hemoglobin (Hb) response, andthe increase in Hb showedan evidentdose-response relationshipwas observed. Whensimilarthedoseswas administered by intravenousor andsubcutaneous injections were similar, boththepatient groupscohortsshowed a similar level of Hb response. There was a tendency for the 카지노사이트 who receivedonceevery-4-week dosing to show more rapid Hb elevation and fluctuation in Hbofover 1 g/dL than in 카지노사이트 who receivedonceevery-2-week dosing. The significance of the present study is that itwais the first study to prove thatonceevery-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 카지노사이트. It was shown in a Phase 3 clinical trial that dialysis 카지노사이트 being treated with epoetin alfa can successfully transition toonceevery-4-week dosing of peginesatide.

최종검토A Phase 2 clinical trial showed that peginesatide was efficacious in treating anemia in 카지노사이트 with chronic kidney disease (CKD). 카지노사이트 who were not on dialysis or received an erythropoiesis-stimulating agent in the 12 weeks prior to the administration of the test drug were sequentially assigned to one of ten cohorts according to the initial dose of peginesatide (weight-based vs. fixed dose), administration route (intravenous vs. subcutaneous injection), and administration frequency (every-2-week vs. every-4-week dosing). Among all 카지노사이트, 96% showed a hemoglobin (Hb) response, and an evident dose-response relationship was observed. When the doses administered by intravenous and subcutaneous injections were similar, the cohorts showed a similar level of Hb response. There was a tendency for the 카지노사이트 who received every-4-week dosing to show more rapid Hb elevation and fluctuation in Hb of over 1 g/dL than in 카지노사이트 who received every-2-week dosing. The significance of the present study is that it is the first study to prove that every-4-week dosing of peginesatide is more effective in increasing or maintaining Hb levels in non-dialysis CKD 카지노사이트. It was shown in a Phase 3 clinical trial that dialysis 카지노사이트 being treated with epoetin alfa can successfully transition to every-4-week dosing of peginesatide.